Compare HBB & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBB | VYGR |
|---|---|---|
| Founded | 1904 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.2M | 216.3M |
| IPO Year | 2017 | 2015 |
| Metric | HBB | VYGR |
|---|---|---|
| Price | $31.11 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 84.8K | ★ 404.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.75 | N/A |
| Revenue | ★ $606,852,000.00 | $10,135,000.00 |
| Revenue This Year | N/A | $34.04 |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | $11.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.56 | $2.94 |
| 52 Week High | $34.26 | $5.55 |
| Indicator | HBB | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 56.22 |
| Support Level | $18.15 | $3.33 |
| Resistance Level | $34.19 | $3.56 |
| Average True Range (ATR) | 1.29 | 0.16 |
| MACD | -0.61 | 0.01 |
| Stochastic Oscillator | 23.68 | 74.03 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.